
Real-world evidence review of long-acting injectable (LAI) versus oral antipsychotics (OA) in treating schizophrenia
02 May 2022
- Comprehensive literature review and meta-analysis of recent published real-world studies compared healthcare use, costs, and medication adherence in patients with schizophrenia treated with LAI versus OA in the United States
- The lower medical costs offset the higher pharmacy costs, resulting in a non-significant difference in total healthcare costs
- Taken together, these findings provide strong evidence on the clinical and economic benefits of LAI compared with OA for the treatment of schizophrenia in the real world